The function of the key protein, transgelin, was studied using CRISPR/Cas9 and RNA interference (RNAi) in cell lines derived from ccRCC tumors to confirm its role in RCC tumor development and sunitinib resistance. This evidence concerns the gene TAGLN and renal cell carcinoma.